Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297

Journal of Clinical Oncology

Volumn 20, Issue 15, 2002, Pages 3270-3275

  Berlin, Jordan D ^a   Catalano, Paul ^a   Thomas, James P ^a   Kugler, John W ^a   Haller, Daniel G ^a   Benson III, Al Bowen ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036682041     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.149     Document Type: Article

References (21)

1. Cancer statistics, 2001
2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
3. Phase II study of gemcitabine in patients with advanced pancreatic cancer
4. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells
5. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT- 29 colon cancer cells
6. A phase I study of gemcitabine, 5-fluorouracil, and leucovorin in patients with advanced, recurrent and/or metastatic solid tumors
7. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E329)
8. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
9. Phase II trial of gemcitabine (GEM), 5-fluorouracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer
10. Phase II trial with gemcitabine (GEM) + 5-fluorouracil (5-FU) in advanced pancreatic cancer (APC)
11. Nonparametric estimation of incomplete observations
12. Evaluation of survival data and two new rank order statistics arising in its consideration
13. Regression models and life tables
14. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
15. Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
16. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A North Central Cancer Treatment Group study
17. Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
18. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer
19. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
20. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: A clinical benefit-oriented phase II study
21. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer: Meta-analysis Group In Cancer